Market Overview

UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Share:
Related ABBV
Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences
US Stock Futures Slip Ahead Of Goldman Sachs Earnings
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog (Zacks)

Jefferies initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and a $44.00 price target.

Jefferies commented, "AbbVie is our top pick for 2013. We see the initial trading volatility post-spin as an opportune entry point into the shares as we soon expect income funds to work the dividend yield down to at least the 4.0% level. A more durable long-term performance from Humira, stronger pipeline delivery and operating margin expansion drive our cash EPS estimates up to 22% ahead of consensus."

AbbVie closed at $34.09 on Tuesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Jan 2015BarclaysMaintainsOverweight
Jan 2015JefferiesMaintainsBuy
Jan 2015Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters